The recall of the emergency anti-allergy medicine spans North America, Europe, Asia and South America. Mylan calls the incidents “extremely rare,” but in the case of a life-saving drug that is administered in emergency situations even one defective product is too many. The St.Louis, Missouri-based company initially did not include the United States in the recall, but later added them to the list. In all, the recall stems from 13 lots distributed during the recall window. Consumers can check the side of the EpiPen box to see if their unit falls within the recalled bunch.

Mylan has caught a lot of heat over the past year for raising prices on consumers. With no competitor on the market, Mylan had continually bumped the costs of their EpiPens, peaking at over $600 — a 600% increase in price since Mylan bought the rights to the drug in 2007. Mylan was also fined $465 million by the US government for scamming Medicare and Medicaid.